var data={"title":"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Francis X McCormack, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Nishant Gupta, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Kevin R Flaherty, MD, MS</a></dd><dd><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 19, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder, belonging to the family of neoplasms with perivascular epithelioid differentiation (PEComa) [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/1\" class=\"abstract_t\">1</a>], that mostly afflicts women and primarily affects the lung [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/2-5\" class=\"abstract_t\">2-5</a>]. The term sporadic LAM is used for patients with LAM who do not have tuberous sclerosis complex (TSC), while TSC-LAM refers to LAM that occurs in patients with TSC. Since the 2000s, studies exploring the pathogenesis of LAM have produced ground-breaking insights into the cellular biochemistry of LAM and have led to the development of an effective treatment. &#160;</p><p>The epidemiology and pathophysiology of sporadic LAM will be reviewed here. The clinical evaluation and treatment of sporadic LAM and the clinical features and diagnosis of TSC and TSC-associated LAM are discussed separately. (See <a href=\"topic.htm?path=tuberous-sclerosis-complex-associated-lymphangioleiomyomatosis-in-adults\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults&quot;</a> and <a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-clinical-presentation-and-diagnostic-evaluation\" class=\"medical medical_review\">&quot;Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation&quot;</a> and <a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Sporadic lymphangioleiomyomatosis: Treatment and prognosis&quot;</a> and <a href=\"topic.htm?path=tuberous-sclerosis-complex-genetics-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex: Genetics, clinical features, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7596684\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The true incidence and prevalence of sporadic LAM are unknown, as the available epidemiological data are observational and frequently include patients with tuberous sclerosis complex (TSC). Nonetheless, clinical experience and most studies confirm that the sporadic variant of LAM is rare and that it almost exclusively affects women. </p><p>Where previous estimates suggested a rate of 1 per million in the general population, regional and national registry data indicate higher rates, possibly reflecting advances in disease recognition and diagnosis [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/6-13\" class=\"abstract_t\">6-13</a>]. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One study that collected data from seven countries, including the United States, the United Kingdom, and Japan, reported that the prevalence of LAM was between 3 and 8 per million women [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/8\" class=\"abstract_t\">8</a>]. &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The LAM Foundation estimated a prevalence of 3 to 5 women per million women [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/14\" class=\"abstract_t\">14</a>]. However, there are currently 1400 women from the United States registered with the LAM Foundation, consistent with a minimum prevalence of 9 per million (assuming United States population of females, 18 years or older of about 122 million). About 10 to 15 percent of registered patients report having TSC. &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a database study from Quebec, the prevalence of LAM was approximately 2 to 3 per million women [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/15\" class=\"abstract_t\">15</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The highest rates of LAM occur in patients with TSC. Briefly, given the estimate of the worldwide prevalence of TSC of one million people (including 0.38 million females age 18 or older) and the conservative projection that 30 percent of women with TSC develop cystic changes consistent with LAM, the number of women with TSC-LAM on earth is predicted to be approximately 100,000. The epidemiology of TSC is discussed separately. (See <a href=\"topic.htm?path=tuberous-sclerosis-complex-associated-lymphangioleiomyomatosis-in-adults#H88312680\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults&quot;, section on 'Epidemiology'</a>.)</p><p/><p>Although LAM can affect all races, one United States registry reported that Caucasians may have a higher prevalence of LAM, especially when compared with individuals of African or Asian descent [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/13\" class=\"abstract_t\">13</a>]. The same registry also reported that LAM was more commonly found in women of higher socioeconomic class; however, apparent racial and ethnic disparities in prevalence may reflect access to healthcare rather than be a true biological phenomenon. </p><p>LAM has rarely been reported in men, most often in association with definite or probable TSC [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/16-21\" class=\"abstract_t\">16-21</a>]. Screening of large TSC clinics revealed cystic changes consistent with LAM in 10 to 13 percent of males [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/22,23\" class=\"abstract_t\">22,23</a>]. There has been only one published case of a male with LAM with no clinical or genotypic evidence of TSC, although limitations in genetic analysis can result in &quot;no mutation detected&quot; in up to 15 percent of patients [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Traditionally, LAM was thought to only affect young premenopausal women of childbearing age. However, studies report LAM in women ranging from preadolescence to old age (on average late 30s to early 40s) [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/5,7,9,13,24-29\" class=\"abstract_t\">5,7,9,13,24-29</a>]. Prepubertal LAM is rare [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/30\" class=\"abstract_t\">30</a>].</p><p>There are no known risk factors, other than TSC, for the development of LAM. While smoking may potentially worsen disease progression it does not appear to be a risk factor for disease induction [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/13\" class=\"abstract_t\">13</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary histopathological abnormality is the proliferation of atypical smooth muscle-like cells (LAM cells) (<a href=\"image.htm?imageKey=PULM%2F66775%7EPULM%2F77252\" class=\"graphic graphic_picture graphicRef66775 graphicRef77252 \">picture 1A-B</a> and <a href=\"image.htm?imageKey=PULM%2F79407\" class=\"graphic graphic_picture graphicRef79407 \">picture 2</a>). Additionally, in the lung, LAM cells are associated with multiple cysts (<a href=\"image.htm?imageKey=PULM%2F64389%7EPULM%2F53690%7EPULM%2F68405\" class=\"graphic graphic_picture graphicRef64389 graphicRef53690 graphicRef68405 \">picture 3A-C</a>) (see <a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-clinical-presentation-and-diagnostic-evaluation#H989132230\" class=\"medical medical_review\">&quot;Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation&quot;, section on 'Tissue pathology'</a>). Significant advances in our understanding of the pathogenesis of LAM have occurred since the early 2000s [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/31-33\" class=\"abstract_t\">31-33</a>]. Accumulating evidence supports a critical role for excessive proliferation of LAM cells due to mutations in tuberous sclerosis complex (TSC) genes, in particular, <em>TSC2</em>. Additional factors that may contribute to cellular proliferation in sporadic LAM include aberrant stimulation of LAM cell growth by estrogen and other growth factors. Processes that promote differentiation (eg, expression of melanoma antigens), migration (estrogen), lymphangiogenesis (vascular endothelial growth factor-D), and tissue destruction (eg, proteases) have also been implicated in the pathogenesis of LAM. It is likely that some combination of these mechanisms best explains the multisystemic nature and unique features that occur in LAM.</p><p>The pathogenesis of TSC is discussed separately. (See <a href=\"topic.htm?path=tuberous-sclerosis-complex-associated-lymphangioleiomyomatosis-in-adults\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2365775679\"><span class=\"h2\">Cellular proliferation</span></p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Tuberous sclerosis gene mutations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the early 2000s, reports from several groups support a dominant role for loss of function of the tuberous sclerosis proteins, tuberin or hamartin, in the pathogenesis of LAM. Tuberin is the protein product of the TSC gene, <em>TSC2</em>, which is located on chromosome 16p13. Tuberin complexes with a sister protein that functions as a scaffold, hamartin, the<em>TSC1</em> gene product encoded on chromosome 9q34 [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/34,35\" class=\"abstract_t\">34,35</a>]. The tuberin-hamartin hetero-oligomer functions as a tumor suppressor complex that inhibits mechanistic target of rapamycin (mTOR; previously called mammalian target of rapamycin), which in turn integrates and controls cellular signals that regulate cell growth, cell size, cell survival, and autophagy (<a href=\"image.htm?imageKey=NEURO%2F58634\" class=\"graphic graphic_figure graphicRef58634 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/36-38\" class=\"abstract_t\">36-38</a>]. Thus, when tuberin or hamartin function is lost, mTOR activity is unrestrained and these processes become unregulated. (See <a href=\"topic.htm?path=tuberous-sclerosis-complex-genetics-clinical-features-and-diagnosis#H6\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex: Genetics, clinical features, and diagnosis&quot;, section on 'Mechanism of tumor formation'</a>.)</p><p>The central role of the loss of functioning tuberin in the pathogenesis of sporadic LAM is supported clinically by the nearly identical pathological presentations of both the sporadic and TSC subtypes of LAM, the high proportion of women with TSC who develop cysts consistent with LAM (up to 80 percent by age 40 years) [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/39\" class=\"abstract_t\">39</a>], and consistent findings of mutations in TSC genes and activation of downstream signals (eg, ribosomal protein S6) in LAM cells derived from patients with both sporadic LAM and TSC-LAM [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/40-48\" class=\"abstract_t\">40-48</a>]. </p><p>Unlike patients with TSC who have germline mutations (ie, genes that are either inherited in a Mendelian autosomal dominant fashion or occur early in embryogenesis and are present in every cell of offspring) of <em>TSC1</em> or <em>TSC2</em>, patients with sporadic LAM have only somatic mutations (ie, mutations limited to the abnormal lesions) in the TSC genes; thus, sporadic LAM is not inheritable. Interestingly, almost all cases of sporadic LAM that have genetic data available are due to mutations in <em>TSC2</em> genes, with one exception [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/49\" class=\"abstract_t\">49</a>], whereas both <em>TSC1</em> and <em>TSC2</em> mutations have been reported in patients with TSC-LAM [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/45,50\" class=\"abstract_t\">45,50</a>]. Where lesions in TSC-associated LAM occur as a result of a germline (first hit) and a somatic (second hit) mutation in one of either <em>TSC1</em> or <em>TSC2</em>, lesion development in sporadic LAM is associated with a somatic mutations in both parental <em>TSC</em> alleles [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/40-47\" class=\"abstract_t\">40-47</a>]. Although low-level somatic mosaicism cannot be excluded (ie, some but not all cells become mutated during embryogenesis), regardless of the mechanism, the end result is deficient or defective tuberin or hamartin in affected cells and dysregulated signaling through the mTOR pathway. &#160;</p><p>Although genetic studies of involved tissues have only been conducted in a limited number of patients with sporadic LAM, they have been consistent in demonstrating loss of functioning tuberin. As examples, early studies revealed somatic <em>TSC2</em> mutations and loss of heterozygosity (LOH) for <em>TSC2</em> in approximately one-half of renal angiomyolipomas in patients with LAM. These mutations were not present in surrounding normal tissue but were identical to mutations found in pulmonary LAM cells [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/40-42\" class=\"abstract_t\">40-42</a>]. Subsequent studies have consistently identified identical mutations and LOH for <em>TSC2</em> in multiple sites, include the lung, angiomyolipomas, chyle, and urine in up to two-thirds of patients with sporadic LAM, suggesting clonal origins [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/43,47,51-53\" class=\"abstract_t\">43,47,51-53</a>]. For those in whom <em>TSC2</em> mutations are not identified, LAM may be due to mutations in <em>TSC </em>genes<em> </em>that are undetected or other unexplored pathogenetic mechanisms. (See <a href=\"topic.htm?path=tuberous-sclerosis-complex-genetics-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex: Genetics, clinical features, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Role of estrogen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical and biologic data support a critical role for female hormones in LAM induction or progression. This role is supported by the predilection of LAM for women (particularly those of childbearing age), reports of disease exacerbations during pregnancy, the menstrual cycle and in response to exogenous estrogens (eg, oral contraception, pregnancy, fertility treatments), the presence of hormonal receptors on LAM cells, and a slower decline in lung function after menopause [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/54-60\" class=\"abstract_t\">54-60</a>]. </p><p>Estrogen has been the primary focus in most LAM studies exploring hormonal influences on disease pathogenesis. Estrogen promotes the proliferation of tuberin null leiomyoma cells as well as LAM-like cells derived from human kidney [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/61\" class=\"abstract_t\">61</a>]. In addition, estrogen promotes the survival and lung metastasis of tuberin-null cells in rodent models [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/62\" class=\"abstract_t\">62</a>]. In another <em>Tsc2</em>-null rodent model, growth of myometrial tumors and secretion of proteolytic enzymes were estrogen-dependent [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/63,64\" class=\"abstract_t\">63,64</a>]. Estrogen has also been shown to promote tuberin null cell invasiveness via matrix metalloproteinases, and through cooperative interactions between the extracellular signal regulated kinase (ERK) and mechanistic target of rapamycin (mTOR) pathways that result in epithelial mesenchymal transition [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/65,66\" class=\"abstract_t\">65,66</a>]. (See <a href=\"#H1185939049\" class=\"local\">'Perivascular epithelioid cell (PEComa)'</a> below.)</p><p>Prolactin is elevated in the serum of LAM patients and is expressed in LAM involved tissues. Higher levels of serum prolactin are associated with greater rates of lung function decline and pneumothorax [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/67\" class=\"abstract_t\">67</a>]. Another study reported that loss of <em>TSC2</em> enhances expression of prolactin receptors and promotes the growth and invasiveness of tuberin null cells [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/68\" class=\"abstract_t\">68</a>]. </p><p>Few studies have addressed the role of hormones other than estrogen and prolactin in LAM progression. While multiple investigators have described the presence of progesterone receptors in LAM lung, their role remains unclear [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/54,68,69\" class=\"abstract_t\">54,68,69</a>]. Although there have been no controlled trials, the most widely quoted retrospective studies did not demonstrate a beneficial effect of progesterone on disease progression [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/57\" class=\"abstract_t\">57</a>]. (See <a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-treatment-and-prognosis#H1045408431\" class=\"medical medical_review\">&quot;Sporadic lymphangioleiomyomatosis: Treatment and prognosis&quot;, section on 'Statins, doxycycline, hormone manipulation'</a>.)</p><p class=\"headingAnchor\" id=\"H679078319\"><span class=\"h3\">Growth factor stimulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The increased expression of growth factors including insulin like growth factor, insulin like growth factor binding protein 5, platelet-derived growth factor, fibroblast growth factor, and vascular endothelial growth factor have all been identified in serum or immunohistochemically in LAM tissue [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/70-73\" class=\"abstract_t\">70-73</a>]. Although their pathogenetic role is unknown, these growth factors presumably stimulate LAM cell growth but may also play a role in tissue differentiation and migration.</p><p class=\"headingAnchor\" id=\"H2971312208\"><span class=\"h2\">Abnormal lymphangiogenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lymphatic clefts (ie, malformed vessels) are present in pulmonary LAM nodules, and LAM is known to involve lymph nodes and lymphatic channels [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/74-76\" class=\"abstract_t\">74-76</a>]. The thoracic duct is often extensively infiltrated by LAM in an ascending pattern at autopsy [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/77\" class=\"abstract_t\">77</a>], suggesting a model for spread based on cycles of implantation, proliferation, and budding that allows LAM cells to &quot;leap frog&quot; toward the venous system in the neck and ultimately reach the pulmonary microvasculature [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/76,78\" class=\"abstract_t\">76,78</a>]. LAM cell clusters (LCCs), comprised of a spherical collection of LAM cells enveloped by a single layer of lymphatic endothelial cells, are found within the lymphatic lumen and in chylous accumulations in the chest and abdomen have been identified in chylous accumulations that occur in LAM [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/79,80\" class=\"abstract_t\">79,80</a>]. The lymphatic manifestations of LAM are discussed separately. (see <a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-clinical-presentation-and-diagnostic-evaluation#H1317599940\" class=\"medical medical_review\">&quot;Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation&quot;, section on 'Cytology'</a> and <a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-clinical-presentation-and-diagnostic-evaluation#H2572532093\" class=\"medical medical_review\">&quot;Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation&quot;, section on 'Lymphatic manifestations'</a>) </p><p>LAM involvement of these tissues is associated with the expression of lymphangiogenic proteins, including vascular endothelial growth factor (VEGF)-C and VEGF&ndash;D, and their receptors, VEGFR-2 and -3, as well as with other lymphatic markers, lymphatic vessel endothelial receptor-1 (LYVE-1) and podoplanin [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/75,79-85\" class=\"abstract_t\">75,79-85</a>]. It has also been postulated that VEGF-D, which is elevated in the serum of women with LAM, may promote lymphangiogenesis and the shedding of LCCs [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/79,84\" class=\"abstract_t\">79,84</a>]. (See <a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-clinical-presentation-and-diagnostic-evaluation#H4160401735\" class=\"medical medical_review\">&quot;Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation&quot;, section on 'Vascular endothelial growth factor-D positive'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Tissue destruction-cyst formation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mechanism of cyst formation that is characteristic of pulmonary LAM is unclear and poorly studied. Some groups have postulated that cyst formation is due to smooth muscle proliferation within the airways, creating a &quot;ball-valve&quot; obstruction that leads to distention of the terminal airspaces, or that tissue degradation is related to an imbalance of proteases and anti-proteases [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/86-95\" class=\"abstract_t\">86-95</a>]. Another theory for the destructive lung remodeling in LAM is that LAM cells that invade the lung and express lymphangiogenic growth factors, such as VEGF-D, drive a program of &quot;frustrated lymphangiogenesis&quot; in the lung that leads to cyst formation [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/78\" class=\"abstract_t\">78</a>].</p><p>Pulmonary LAM nodules contain matrix metalloproteinase (MMP)-1, -2, -3, -9, -11, and -14 as well as MMP activators and MMP inhibitors, TIMP-1 and TIMP-2 [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/91,93-95\" class=\"abstract_t\">91,93-95</a>]. MMP-2 [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/96\" class=\"abstract_t\">96</a>] and MMP-9 [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/97\" class=\"abstract_t\">97</a>] have also been reported to be elevated in serum. Elevated expression of cathepsin K, a serine protease, has also been reported in LAM lung lesions [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/98\" class=\"abstract_t\">98</a>]. It is unknown which of these and other proteases are directly involved in cyst formation, cell invasion, cell migration, differentiation, or remodeling [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/99\" class=\"abstract_t\">99</a>]. </p><p class=\"headingAnchor\" id=\"H4183916503\"><span class=\"h2\">Other</span></p><p class=\"headingAnchor\" id=\"H2812896068\"><span class=\"h3\">Recruitment of stromal cells</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genetic studies indicate that only a fraction of cells (in some cases &lt;10 percent) within the LAM lesion contain mutations in TSC genes, and the remaining cells are likely recruited into the LAM lesion [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/100\" class=\"abstract_t\">100</a>]. Recruited cells include fibroblasts [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/101\" class=\"abstract_t\">101</a>], mast cells [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/70\" class=\"abstract_t\">70</a>], and neutrophils and lymphocytes [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/100\" class=\"abstract_t\">100</a>]. As with all cancers, cooperative interactions between mutant cells and stromal cells plays a major role in disease pathogenesis [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/102\" class=\"abstract_t\">102</a>]. Their exact role in LAM remains undetermined.</p><p class=\"headingAnchor\" id=\"H2726395566\"><span class=\"h3\">Modulation of autophagy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As nutrients become limiting, cells regulate their metabolic state to sustain viability. A cellular program of bulk degradation of organelles and macromolecules called autophagy is deployed to generate substrate for generation of cellular biomass. Inappropriate activation of mTOR by TSC mutations simulates a fed state, and both stimulates proliferation and suppresses autophagy, which may limit cell growth in environments where nutrients are limiting [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/103\" class=\"abstract_t\">103</a>]. </p><p class=\"headingAnchor\" id=\"H3651690968\"><span class=\"h3\">Altered cellular metabolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>mTOR is part of a complex (together with Raptor, Rictor, Sin) that forms the nexus of multiple cellular signaling networks and functions to balance metabolic supply with demand [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/104\" class=\"abstract_t\">104</a>]. Mutations in mTOR mediate altered cellular metabolism that facilitate neoplastic growth, including a shift from oxidative phosphorylation to glycolysis as a mechanism to increase availability of metabolic substrate for generation of cellular biomass and for tolerance of anaerobic environments [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/105\" class=\"abstract_t\">105</a>]. LAM cells take up glutamine as an alternative carbon source, which provides an adaptive mechanism to fuel mTOR activity when glucose pathways are insufficient to support it or are blocked [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/106\" class=\"abstract_t\">106</a>]. In addition, activation of mTOR drives flux through purine and pyrimidine biosynthesis pathways and the pentose phosphate shunt pathway to provide substrate for the synthesis of polynucleotides, and activates super conserved receptor expressed in brain (SREB) which is required for the biosynthesis of fatty acids and cholesterol [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/107,108\" class=\"abstract_t\">107,108</a>]. Finally, activated mTOR stimulates ribonucleic acid (RNA) translation by regulating the assembly of the eukaryotic translation initiation factor (eIF4F) complex and phosphorylating downstream targets including eIF4F binding proteins (4E-BPs) and ribosomal protein S6 kinases [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/109\" class=\"abstract_t\">109</a>]. </p><p class=\"headingAnchor\" id=\"H110567975\"><span class=\"h3\">Miscellaneous</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other factors that have been found to be abnormally expressed in LAM include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High Mobility Group 2A [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/110\" class=\"abstract_t\">110</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adipocyte phospholipase A2 [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/111\" class=\"abstract_t\">111</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Survivin [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/112\" class=\"abstract_t\">112</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteopontin [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/113\" class=\"abstract_t\">113</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HIF1alpha targets</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythropoietin [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/114\" class=\"abstract_t\">114</a>] </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Metastasis and invasion markers (eg, CD44V and CXCR4) [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/113,115\" class=\"abstract_t\">113,115</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Src kinase [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/116\" class=\"abstract_t\">116</a>] </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Plasminogen system [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/117\" class=\"abstract_t\">117</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urotensin [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/118\" class=\"abstract_t\">118</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CA-125 [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/119\" class=\"abstract_t\">119</a>]</p><p/><p class=\"headingAnchor\" id=\"H3035674177\"><span class=\"h1\">LAM CELL ORIGIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The origin of the LAM cells, which are included in the family of neoplasms with perivascular epithelioid differentiation (PEComa), is unknown. Theories for the source of LAM cells that populate the lung include the neural crest, uterus [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/64,120\" class=\"abstract_t\">64,120</a>], angiomyolipoma [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/121\" class=\"abstract_t\">121</a>], the bone marrow, or the lymphatic system. Evidence to support potential sources is described in the sections below. </p><p class=\"headingAnchor\" id=\"H1185939049\"><span class=\"h2\">Perivascular epithelioid cell (PEComa)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>LAM was originally considered an interstitial lung disease, but it is now classified by the World Health Organization (WHO) as a lung tumor, in the perivascular epithelioid cell (ie, PEComa) family [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/122-124\" class=\"abstract_t\">122-124</a>], which also includes angiomyolipomas, clear cell carcinomas, and other rare neoplasms of visceral organs. The classification of LAM as a low grade neoplasm is based upon the observations that LAM cells exhibit cellular and genetic fingerprints similar to neoplasms [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/123\" class=\"abstract_t\">123</a>], have loss of heterozygosity (LOH) for the tumor suppressor gene <em>TSC2</em>, can recur in transplanted lung, exhibit <span class=\"nowrap\">invasive/migratory/metastatic</span> behavior [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/35,41,51,79,98,125\" class=\"abstract_t\">35,41,51,79,98,125</a>], and have the capacity to destroy remote organs. </p><p class=\"headingAnchor\" id=\"H1857000101\"><span class=\"h2\">Neural crest (melanoma antigen expression)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A monoclonal antibody to human melanoma black (HMB)-45 (also known as melanosome specific antigen), derived from melanoma hybridomas, is the classic marker for the diagnosis of LAM on lung biopsy (<a href=\"image.htm?imageKey=PULM%2F55243\" class=\"graphic graphic_picture graphicRef55243 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/126,127\" class=\"abstract_t\">126,127</a>] but can also be found in angiomyolipomas and some uterine PEComas [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/128-130\" class=\"abstract_t\">128-130</a>]. </p><p>The antigen to which HMB-45 binds has total cDNA homology with the gene, premelanosome protein (Pmel 17, located on chromosome 12), the product of which is involved in the synthesis of melanin and catecholamines from the amino acid tyrosine, suggesting a neuroendocrine origin.</p><p>Immunohistochemical staining of LAM lung or cells in culture have shown that pulmonary LAM cells aberrantly express the epitope for HMB-45 as well as other melanoma-derived antigens, further supporting the hypothesis that LAM cells may be of neuroendocrine origin and may be responsible for LAM cell differentiation [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/131-135\" class=\"abstract_t\">131-135</a>]. However, immunoreactivity for HMB-45 can be sporadic and variable, and rarely even absent in LAM lesions. LAM cells stain for other melanocytic proteins, including PNL2 [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/136\" class=\"abstract_t\">136</a>], MART1 [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/131\" class=\"abstract_t\">131</a>], and aPep13h [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/133\" class=\"abstract_t\">133</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H2433390856\"><span class=\"h2\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other purported origins for the LAM cell include the lymphatics [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/85\" class=\"abstract_t\">85</a>], the kidney (eg, from angiomyolipomas) [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/121\" class=\"abstract_t\">121</a>], or the uterus [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/63,64,120,122\" class=\"abstract_t\">63,64,120,122</a>]. Data to support these origins come from studies that report that LAM cells in the lung are morphologically or genetically similar to neoplastic cells in these organs [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/40-44,51,79,85,137\" class=\"abstract_t\">40-44,51,79,85,137</a>]. A study showed that <em>Tsc2</em> inactivation in mice resulted in the development of uterine myometrial tumors with features similar to LAM. In addition, in almost half of the animals, these tumors metastasized to the lungs, thus suggesting the uterus as a possible source of origin for LAM cells [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/63,64\" class=\"abstract_t\">63,64</a>]. Although case reports of LAM in the uterus have been described, it remains possible that the uterus is another target for metastasis rather than the primary source, and the evidence for the uterus as the definitive source of LAM cells remains inconclusive [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/120,138\" class=\"abstract_t\">120,138</a>]. </p><p class=\"headingAnchor\" id=\"H181867476\"><span class=\"h1\">RESEARCH MODELS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Experimental modeling is critical for effective LAM research. While cellular and animal models of TSC and LAM have been published, all have limitations. The most commonly used cell models for LAM are ELT3 cells, a uterine leiomyoma cell line from the Eker rat which has a germ line mutation in <em>TSC2</em> [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/139\" class=\"abstract_t\">139</a>], TSC null murine embryonic fibroblast cell lines [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/140\" class=\"abstract_t\">140</a>], 621 to 101 cells, a transformed cell line from a renal angiomyolipoma [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/141\" class=\"abstract_t\">141</a>], and low passage mixed cultures isolated from LAM lung at the time of transplant [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/48\" class=\"abstract_t\">48</a>]. Animal models for LAM that have been reported include uterus specific <em>TSC2</em> deletion [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/63\" class=\"abstract_t\">63</a>], subcutaneous xenograft models [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/62,142\" class=\"abstract_t\">62,142</a>], and endonasal <em>TSC2</em> null cell administration [<a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/143\" class=\"abstract_t\">143</a>]. </p><p class=\"headingAnchor\" id=\"H7594517\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphangioleiomyomatosis (LAM) is a rare multisystem disease with a female predilection that is characterized by cyst formation in the lung and the proliferation of immature smooth muscle with features of perivascular epithelioid cells (LAM cells) in affected organs. The term sporadic LAM is used for patients with LAM who do not have tuberous sclerosis complex (TSC), while TSC-LAM refers to LAM that is associated with TSC. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Estimates of the prevalence of sporadic LAM vary, ranging from 1 to 9 per million women in the general population with the highest rates in women with TSC (more than 30 percent). (See <a href=\"#H7596684\" class=\"local\">'Epidemiology'</a> above and <a href=\"topic.htm?path=tuberous-sclerosis-complex-associated-lymphangioleiomyomatosis-in-adults#H641776278\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The exact pathogenesis of LAM is unknown, but appears to involve excessive proliferation of LAM cells due to loss of functioning TSC genes. Loss of heterozygosity and somatic mutations for the <em>TSC2</em> gene are found in affected tissue in the majority of sporadic LAM cases, but TSC mutations are not present in the germ line such that sporadic LAM cannot be inherited. The absence of tuberin prevents formation of the hamartin-tuberin complex, which regulates mechanistic (previously mammalian) target of rapamycin (mTOR), a molecule that controls cell growth and cell size. (See <a href=\"#H6\" class=\"local\">'Tuberous sclerosis gene mutations'</a> above and <a href=\"topic.htm?path=tuberous-sclerosis-complex-genetics-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Tuberous sclerosis complex: Genetics, clinical features, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hormonal fluxes (eg, pregnancy, exogenous estrogens) clearly play a key role in the pathogenesis of LAM. In particular, an important role for estrogen is suggested by the presence of estrogen receptors on LAM cells and a slower decline in lung function after menopause. Estrogen may also play a role in cell invasion and migration. (See <a href=\"#H7\" class=\"local\">'Role of estrogen'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormal lymphangiogenesis may play role in cell migration and disease progression as evidenced by lymphatic differentiation within LAM lesions and extensive involvement of lymphatic channels by LAM cells. (See <a href=\"#H2971312208\" class=\"local\">'Abnormal lymphangiogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The mechanism of cyst formation in LAM lung is unclear but may involve bronchial obstruction, tissue destruction by proteases, or dysregulated lymphangiogenesis. (See <a href=\"#H8\" class=\"local\">'Tissue destruction-cyst formation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>LAM pathogenesis also involves recruitment of stromal cells, metabolic reprogramming of the LAM cell (eg, upregulation of glycolysis, increased synthesis of lipids, protein, and nucleotides), promotion of cell survival, and inhibition of autophagy. (See <a href=\"#H4183916503\" class=\"local\">'Other'</a> above.) &#160; </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The exact origin of LAM cells that populate the lung is unknown. LAM is included in the family of neoplasms with perivascular epithelioid differentiation (PEComa). Other evidence, such as cell surface positivity for the human melanoma black (HMB)-45 antigen, suggests a neuroendocrine origin. (See <a href=\"#H3035674177\" class=\"local\">'Lam cell origin'</a> above and <a href=\"#H181867476\" class=\"local\">'Research models'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1145705202\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Talmadge E King, Jr, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/1\" class=\"nounderline abstract_t\">Thway K, Fisher C. PEComa: morphology and genetics of a complex tumor family. Ann Diagn Pathol 2015; 19:359.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/2\" class=\"nounderline abstract_t\">Kalassian KG, Doyle R, Kao P, et al. Lymphangioleiomyomatosis: new insights. Am J Respir Crit Care Med 1997; 155:1183.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/3\" class=\"nounderline abstract_t\">Sullivan EJ. Lymphangioleiomyomatosis: a review. Chest 1998; 114:1689.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/4\" class=\"nounderline abstract_t\">NHLBI Workshop Summary. Report of workshop on lymphangioleiomyomatosis. National Heart, Lung, and Blood Institute. Am J Respir Crit Care Med 1999; 159:679.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/5\" class=\"nounderline abstract_t\">Johnson S. Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Thorax 1999; 54:254.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/6\" class=\"nounderline abstract_t\">Moss J, Avila NA, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001; 164:669.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/7\" class=\"nounderline abstract_t\">Hancock E, Osborne J. Lymphangioleiomyomatosis: a review of the literature. Respir Med 2002; 96:1.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/8\" class=\"nounderline abstract_t\">Harknett EC, Chang WY, Byrnes S, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 2011; 104:971.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/9\" class=\"nounderline abstract_t\">Baldi BG, Freitas CS, Araujo MS, et al. Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:129.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/10\" class=\"nounderline abstract_t\">Park HY, Nam HS, Chung MP, et al. A nationwide survey of lymphangioleiomyomatosis in Korea: recent increase in newly diagnosed patients. J Korean Med Sci 2010; 25:1182.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/11\" class=\"nounderline abstract_t\">Hayashida M, Seyama K, Inoue Y, et al. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 2007; 12:523.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/12\" class=\"nounderline abstract_t\">Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55:1052.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/13\" class=\"nounderline abstract_t\">Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173:105.</a></li><li class=\"breakAll\">The LAM Foundation. https://www.thelamfoundation.org/Newly-Diagnosed/Learning-About-Lam/About-LAM (Accessed on April 22, 2016).</li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/15\" class=\"nounderline abstract_t\">Kristof AS, Li PZ, Major P, Landry JS. Lymphangioleiomyomatosis and Tuberous Sclerosis Complex in Quebec: Prevalence and Health-care Utilization. Chest 2015; 148:444.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/16\" class=\"nounderline abstract_t\">Aubry MC, Myers JL, Ryu JH, et al. Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med 2000; 162:749.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/17\" class=\"nounderline abstract_t\">Miyake M, Tateishi U, Maeda T, et al. Pulmonary lymphangioleiomyomatosis in a male patient with tuberous sclerosis complex. Radiat Med 2005; 23:525.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/18\" class=\"nounderline abstract_t\">Kim NR, Chung MP, Park CK, et al. Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man. Pathol Int 2003; 53:231.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/19\" class=\"nounderline abstract_t\">Schiavina M, Di Scioscio V, Contini P, et al. Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am J Respir Crit Care Med 2007; 176:96.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/20\" class=\"nounderline abstract_t\">Wakida K, Watanabe Y, Kumasaka T, et al. Lymphangioleiomyomatosis in a Male. Ann Thorac Surg 2015; 100:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/21\" class=\"nounderline abstract_t\">Yamanaka S, Mizobuchi T, Kurihara M. Two Kinds of Cystic Lung Lesions with Pulmonary Lymphangioleiomyomatosis in a Male. Ann Thorac Cardiovasc Surg 2017; 23:36.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/22\" class=\"nounderline abstract_t\">Muzykewicz DA, Sharma A, Muse V, et al. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med Genet 2009; 46:465.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/23\" class=\"nounderline abstract_t\">Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, et al. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol 2011; 66:625.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/24\" class=\"nounderline abstract_t\">Restrepo-Gualteros SM, Rodriguez-Martinez CE, Jaramillo-Barberi LE, et al. Adolescent form of sporadic lymphangioleiomyomatosis (S-LAM). Allergol Immunopathol (Madr) 2015; 43:111.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/25\" class=\"nounderline abstract_t\">Richter MJ, Baumgartner R, Leuchte HH. [Chylothorax in an 87-year-old patient]. Internist (Berl) 2013; 54:105.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/26\" class=\"nounderline abstract_t\">Kebria M, Black D, Borelli C, et al. Primary retroperitoneal lymphangioleiomyomatosis in a postmenopausal woman: a case report and review of the literature. Int J Gynecol Cancer 2007; 17:528.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/27\" class=\"nounderline abstract_t\">Zanella A, Toppan P, Nitti D, Lise M. Pulmonary lymphangioleiomyomatosis: a case report in postmenopausal woman treated with pleurodesis and progesterone (medroxyprogesterone acetate). Tumori 1996; 82:96.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/28\" class=\"nounderline abstract_t\">Nagy B, N&aacute;br&aacute;dy Z, Nemes Z. Pulmonary lymphangiomyomatosis in a preadolescent girl. N Engl J Med 1998; 338:473.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/29\" class=\"nounderline abstract_t\">Ho TB, Hull JH, Hughes NC. An 86-year-old female with lymphangioleiomyomatosis. Eur Respir J 2006; 28:1065.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/30\" class=\"nounderline abstract_t\">Ciftci AO, Sanlialp I, Tanyel FC, Buyukpamuk&ccedil;u N. The association of pulmonary lymphangioleiomyomatosis with renal and hepatic angiomyolipomas in a prepubertal girl: a previously unreported entity. Respiration 2007; 74:335.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/31\" class=\"nounderline abstract_t\">Harari S, Torre O, Cassandro R, Moss J. The changing face of a rare disease: lymphangioleiomyomatosis. Eur Respir J 2015; 46:1471.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/32\" class=\"nounderline abstract_t\">Taveira-DaSilva AM, Moss J. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin Epidemiol 2015; 7:249.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/33\" class=\"nounderline abstract_t\">Meraj R, Wikenheiser-Brokamp KA, Young LR, McCormack FX. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med 2012; 33:486.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/34\" class=\"nounderline abstract_t\">Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994; 6:193.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/35\" class=\"nounderline abstract_t\">Goncharova EA, Goncharov DA, Lim PN, et al. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006; 34:473.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/36\" class=\"nounderline abstract_t\">Rosner M, Hanneder M, Siegel N, et al. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res 2008; 658:234.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/37\" class=\"nounderline abstract_t\">Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40:310.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/38\" class=\"nounderline abstract_t\">Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/39\" class=\"nounderline abstract_t\">Cudzilo CJ, Szczesniak RD, Brody AS, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013; 144:578.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/40\" class=\"nounderline abstract_t\">Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998; 62:810.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/41\" class=\"nounderline abstract_t\">Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2000; 97:6085.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/42\" class=\"nounderline abstract_t\">Astrinidis A, Khare L, Carsillo T, et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 2000; 37:55.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/43\" class=\"nounderline abstract_t\">Cai X, Pacheco-Rodriguez G, Fan QY, et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med 2010; 182:1410.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/44\" class=\"nounderline abstract_t\">Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 2001; 164:1537.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/45\" class=\"nounderline abstract_t\">Sato T, Seyama K, Fujii H, et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 2002; 47:20.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/46\" class=\"nounderline abstract_t\">Ando K, Fujino N, Mitani K, et al. Isolation of individual cellular components from lung tissues of patients with lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 2016; 310:L899.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/47\" class=\"nounderline abstract_t\">Fujita A, Ando K, Kobayashi E, et al. Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing. Hum Genet 2016; 135:61.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/48\" class=\"nounderline abstract_t\">Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002; 277:30958.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/49\" class=\"nounderline abstract_t\">Sato T, Seyama K, Kumasaka T, et al. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis. J Intern Med 2004; 256:166.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/50\" class=\"nounderline abstract_t\">Jones AC, Shyamsundar MM, Thomas MW, et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64:1305.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/51\" class=\"nounderline abstract_t\">Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2004; 101:17462.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/52\" class=\"nounderline abstract_t\">Bittmann I, Rolf B, Amann G, L&ouml;hrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol 2003; 34:95.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/53\" class=\"nounderline abstract_t\">Bittmann I, Dose TB, M&uuml;ller C, et al. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol 1997; 28:1420.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/54\" class=\"nounderline abstract_t\">Berger U, Khaghani A, Pomerance A, et al. Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. Am J Clin Pathol 1990; 93:609.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/55\" class=\"nounderline abstract_t\">Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 1991; 96:529.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/56\" class=\"nounderline abstract_t\">Matsui K, Takeda K, Yu ZX, et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med 2000; 161:1002.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/57\" class=\"nounderline abstract_t\">Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126:1867.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/58\" class=\"nounderline abstract_t\">Brunelli A, Catalini G, Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynaecol Obstet 1996; 52:289.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/59\" class=\"nounderline abstract_t\">Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 2002; 57:1085.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/60\" class=\"nounderline abstract_t\">Kanemura H, Jinta T, Tamura T. Pulmonary lymphangioleiomyomatosis and fertility treatment. QJM 2018; 111:123.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/61\" class=\"nounderline abstract_t\">Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 2004; 286:L694.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/62\" class=\"nounderline abstract_t\">Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A 2009; 106:2635.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/63\" class=\"nounderline abstract_t\">Prizant H, Taya M, Lerman I, et al. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model. Endocr Relat Cancer 2016; 23:265.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/64\" class=\"nounderline abstract_t\">Prizant H, Sen A, Light A, et al. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs. Mol Endocrinol 2013; 27:1403.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/65\" class=\"nounderline abstract_t\">Glassberg MK, Elliot SJ, Fritz J, et al. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. J Clin Endocrinol Metab 2008; 93:1625.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/66\" class=\"nounderline abstract_t\">Gu X, Yu JJ, Ilter D, et al. Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. Proc Natl Acad Sci U S A 2013; 110:14960.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/67\" class=\"nounderline abstract_t\">Terasaki Y, Yahiro K, Pacheco-Rodriguez G, et al. Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 2010; 182:531.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/68\" class=\"nounderline abstract_t\">Alkharusi A, Lesma E, Ancona S, et al. Role of Prolactin Receptors in Lymphangioleiomyomatosis. PLoS One 2016; 11:e0146653.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/69\" class=\"nounderline abstract_t\">Gao L, Yue MM, Davis J, et al. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. Virchows Arch 2014; 464:495.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/70\" class=\"nounderline abstract_t\">Inoue Y, King TE Jr, Barker E, et al. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med 2002; 166:765.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/71\" class=\"nounderline abstract_t\">Clements D, Asprey SL, McCulloch TA, et al. Analysis of the oestrogen response in an angiomyolipoma derived xenograft model. Endocr Relat Cancer 2009; 16:59.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/72\" class=\"nounderline abstract_t\">Lesma E, Grande V, Carelli S, et al. Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor. Am J Pathol 2005; 167:1093.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/73\" class=\"nounderline abstract_t\">Ding M, Bruick RK, Yu Y. Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling. Nat Cell Biol 2016; 18:319.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/74\" class=\"nounderline abstract_t\">Davis JM, Hyjek E, Husain AN, et al. Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells. J Histochem Cytochem 2013; 61:580.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/75\" class=\"nounderline abstract_t\">Gupta R, Kitaichi M, Inoue Y, et al. Lymphatic manifestations of lymphangioleiomyomatosis. Lymphology 2014; 47:106.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/76\" class=\"nounderline abstract_t\">Seyama K, Kumasaka T, Kurihara M, et al. Lymphangioleiomyomatosis: a disease involving the lymphatic system. Lymphat Res Biol 2010; 8:21.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/77\" class=\"nounderline abstract_t\">Cornog JL Jr, Enterline HT. Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer 1966; 19:1909.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/78\" class=\"nounderline abstract_t\">Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep's clothing. J Clin Invest 2012; 122:3807.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/79\" class=\"nounderline abstract_t\">Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005; 29:1356.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/80\" class=\"nounderline abstract_t\">Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol 2004; 28:1007.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/81\" class=\"nounderline abstract_t\">Young L, Lee HS, Inoue Y, et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013; 1:445.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/82\" class=\"nounderline abstract_t\">Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006; 4:143.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/83\" class=\"nounderline abstract_t\">Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009; 135:1293.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/84\" class=\"nounderline abstract_t\">Mitani K, Kumasaka T, Takemura H, et al. Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis. Acta Cytol 2009; 53:402.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/85\" class=\"nounderline abstract_t\">Yue M, Pacheco G, Cheng T, et al. Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis. Am J Pathol 2016; 186:1825.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/86\" class=\"nounderline abstract_t\">Fukuda Y, Kawamoto M, Yamamoto A, et al. Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis. Hum Pathol 1990; 21:1252.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/87\" class=\"nounderline abstract_t\">Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis. A review. Am J Pathol 1975; 79:348.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/88\" class=\"nounderline abstract_t\">Sobonya RE, Quan SF, Fleishman JS. Pulmonary lymphangioleiomyomatosis: quantitative analysis of lesions producing airflow limitation. Hum Pathol 1985; 16:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/89\" class=\"nounderline abstract_t\">McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008; 133:507.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/90\" class=\"nounderline abstract_t\">Abbott GF, Rosado-de-Christenson ML, Frazier AA, et al. From the archives of the AFIP: lymphangioleiomyomatosis: radiologic-pathologic correlation. Radiographics 2005; 25:803.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/91\" class=\"nounderline abstract_t\">Matsui K, Takeda K, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000; 124:267.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/92\" class=\"nounderline abstract_t\">Krymskaya VP, Shipley JM. Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 2003; 28:546.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/93\" class=\"nounderline abstract_t\">Zhe X, Yang Y, Jakkaraju S, Schuger L. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol 2003; 28:504.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/94\" class=\"nounderline abstract_t\">Odajima N, Betsuyaku T, Nasuhara Y, et al. Matrix metalloproteinases in blood from patients with LAM. Respir Med 2009; 103:124.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/95\" class=\"nounderline abstract_t\">Goncharova EA, Goncharov DA, Fehrenbach M, et al. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med 2012; 4:154ra134.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/96\" class=\"nounderline abstract_t\">Chang WY, Cane JL, Blakey JD, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res 2012; 13:34.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/97\" class=\"nounderline abstract_t\">Pimenta SP, Baldi BG, Acencio MM, et al. Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade. J Bras Pneumol 2011; 37:424.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/98\" class=\"nounderline abstract_t\">Chilosi M, Pea M, Martignoni G, et al. Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Mod Pathol 2009; 22:161.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/99\" class=\"nounderline abstract_t\">B&uuml;hling F, Groneberg D, Welte T. Proteases and their role in chronic inflammatory lung diseases. Curr Drug Targets 2006; 7:751.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/100\" class=\"nounderline abstract_t\">Badri KR, Gao L, Hyjek E, et al. Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 2013; 187:663.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/101\" class=\"nounderline abstract_t\">Clements D, Dongre A, Krymskaya VP, Johnson SR. Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis. PLoS One 2015; 10:e0126025.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/102\" class=\"nounderline abstract_t\">Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/103\" class=\"nounderline abstract_t\">Yu J, Parkhitko AA, Henske EP. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy. Proc Am Thorac Soc 2010; 7:48.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/104\" class=\"nounderline abstract_t\">Choo AY, Kim SG, Vander Heiden MG, et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 2010; 38:487.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/105\" class=\"nounderline abstract_t\">Sun Q, Chen X, Ma J, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 2011; 108:4129.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/106\" class=\"nounderline abstract_t\">Fu V, Moroishi T, Guan KL. Glycoholics Anonymous: Cancer Sobers Up with mTORC1. Cancer Cell 2016; 29:432.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/107\" class=\"nounderline abstract_t\">Ben-Sahra I, Hoxhaj G, Ricoult SJ, et al. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 2016; 351:728.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/108\" class=\"nounderline abstract_t\">Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013; 339:1323.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/109\" class=\"nounderline abstract_t\">Bhat M, Robichaud N, Hulea L, et al. Targeting the translation machinery in cancer. Nat Rev Drug Discov 2015; 14:261.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/110\" class=\"nounderline abstract_t\">D'Armiento J, Shiomi T, Marks S, et al. Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation. Cancer Res 2016; 76:844.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/111\" class=\"nounderline abstract_t\">Li C, Zhang E, Sun Y, et al. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis. PLoS One 2014; 9:e104809.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/112\" class=\"nounderline abstract_t\">Carelli S, Lesma E, Paratore S, et al. Survivin expression in tuberous sclerosis complex cells. Mol Med 2007; 13:166.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/113\" class=\"nounderline abstract_t\">Pacheco-Rodriguez G, Steagall WK, Crooks DM, et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res 2007; 67:10573.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/114\" class=\"nounderline abstract_t\">Ikeda Y, Taveira-DaSilva AM, Pacheco-Rodriguez G, et al. Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2. Am J Physiol Lung Cell Mol Physiol 2011; 300:L64.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/115\" class=\"nounderline abstract_t\">Clements D, Markwick LJ, Puri N, Johnson SR. Role of the CXCR4/CXCL12 axis in lymphangioleiomyomatosis and angiomyolipoma. J Immunol 2010; 185:1812.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/116\" class=\"nounderline abstract_t\">Tyryshkin A, Bhattacharya A, Eissa NT. SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis. Cancer Res 2014; 74:1996.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/117\" class=\"nounderline abstract_t\">Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. Am J Respir Cell Mol Biol 2005; 32:28.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/118\" class=\"nounderline abstract_t\">Kristof AS, You Z, Han YS, Giaid A. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis. Peptides 2010; 31:1511.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/119\" class=\"nounderline abstract_t\">Glasgow CG, Pacheco-Rodriguez G, Steagall WK, et al. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis. Chest 2018; 153:339.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/120\" class=\"nounderline abstract_t\">Hayashi T, Kumasaka T, Mitani K, et al. Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. Am J Surg Pathol 2011; 35:1776.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/121\" class=\"nounderline abstract_t\">Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003; 38:376.</a></li><li class=\"breakAll\">Travis WD, Brambilla EW, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, IARC Press, Lyon 2015.</li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/123\" class=\"nounderline abstract_t\">McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012; 186:1210.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/124\" class=\"nounderline abstract_t\">Martignoni G, Pea M, Reghellin D, et al. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med 2010; 134:33.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/125\" class=\"nounderline abstract_t\">Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003; 167:976.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/126\" class=\"nounderline abstract_t\">Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115:1041.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/127\" class=\"nounderline abstract_t\">Grzegorek I, Lenze D, Chabowski M, et al. Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis. Anticancer Res 2015; 35:3353.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/128\" class=\"nounderline abstract_t\">Yavuz E, Cakr C, Tuzlal S, et al. Uterine perivascular epithelioid cell tumor coexisting with pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a case report. Appl Immunohistochem Mol Morphol 2008; 16:405.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/129\" class=\"nounderline abstract_t\">Vang R, Kempson RL. Perivascular epithelioid cell tumor ('PEComa') of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol 2002; 26:1.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/130\" class=\"nounderline abstract_t\">Aydin H, Magi-Galluzzi C, Lane BR, et al. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol 2009; 33:289.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/131\" class=\"nounderline abstract_t\">Klarquist J, Barfuss A, Kandala S, et al. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol 2009; 175:2463.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/132\" class=\"nounderline abstract_t\">Matsumoto Y, Horiba K, Usuki J, et al. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999; 21:327.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/133\" class=\"nounderline abstract_t\">Valencia JC, Steagall WK, Zhang Y, et al. Antibody &alpha;PEP13h reacts with lymphangioleiomyomatosis cells in lung nodules. Chest 2015; 147:771.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/134\" class=\"nounderline abstract_t\">Gilbert ER, Eby JM, Hammer AM, et al. Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis. Am J Pathol 2013; 183:226.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/135\" class=\"nounderline abstract_t\">Delaney SP, Julian LM, Stanford WL. The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis. Front Cell Dev Biol 2014; 2:69.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/136\" class=\"nounderline abstract_t\">Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 2004; 52:1537.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/137\" class=\"nounderline abstract_t\">Hammes SR, Krymskaya VP. Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM). Horm Cancer 2013; 4:70.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/138\" class=\"nounderline abstract_t\">Taveira-Dasilva AM, Rabel A, Gochuico BR, et al. Prevalence of uterine leiomyomas in lymphangioleiomyomatosis. Fertil Steril 2011; 96:711.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/139\" class=\"nounderline abstract_t\">Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 1995; 136:4996.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/140\" class=\"nounderline abstract_t\">Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007; 117:730.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/141\" class=\"nounderline abstract_t\">Lee PS, Tsang SW, Moses MA, et al. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol 2010; 42:227.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/142\" class=\"nounderline abstract_t\">Atochina-Vasserman EN, Abramova E, James ML, et al. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 2015; 309:L1447.</a></li><li><a href=\"https://www.uptodate.com/contents/sporadic-lymphangioleiomyomatosis-epidemiology-and-pathogenesis/abstract/143\" class=\"nounderline abstract_t\">Lesma E, Eloisa C, Isaia E, et al. Development of a lymphangioleiomyomatosis model by endonasal administration of human TSC2-/- smooth muscle cells in mice. Am J Pathol 2012; 181:947.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4335 Version 32.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H7594517\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H7596684\" id=\"outline-link-H7596684\">EPIDEMIOLOGY</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">PATHOGENESIS</a><ul><li><a href=\"#H2365775679\" id=\"outline-link-H2365775679\">Cellular proliferation</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Tuberous sclerosis gene mutations</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Role of estrogen</a></li><li><a href=\"#H679078319\" id=\"outline-link-H679078319\">- Growth factor stimulation</a></li></ul></li><li><a href=\"#H2971312208\" id=\"outline-link-H2971312208\">Abnormal lymphangiogenesis</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Tissue destruction-cyst formation</a></li><li><a href=\"#H4183916503\" id=\"outline-link-H4183916503\">Other</a><ul><li><a href=\"#H2812896068\" id=\"outline-link-H2812896068\">- Recruitment of stromal cells</a></li><li><a href=\"#H2726395566\" id=\"outline-link-H2726395566\">- Modulation of autophagy</a></li><li><a href=\"#H3651690968\" id=\"outline-link-H3651690968\">- Altered cellular metabolism</a></li><li><a href=\"#H110567975\" id=\"outline-link-H110567975\">- Miscellaneous</a></li></ul></li></ul></li><li><a href=\"#H3035674177\" id=\"outline-link-H3035674177\">LAM CELL ORIGIN</a><ul><li><a href=\"#H1185939049\" id=\"outline-link-H1185939049\">Perivascular epithelioid cell (PEComa)</a></li><li><a href=\"#H1857000101\" id=\"outline-link-H1857000101\">Neural crest (melanoma antigen expression)</a></li><li><a href=\"#H2433390856\" id=\"outline-link-H2433390856\">Other</a></li></ul></li><li><a href=\"#H181867476\" id=\"outline-link-H181867476\">RESEARCH MODELS</a></li><li><a href=\"#H7594517\" id=\"outline-link-H7594517\">SUMMARY</a></li><li><a href=\"#H1145705202\" id=\"outline-link-H1145705202\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/4335|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/58634\" class=\"graphic graphic_figure\">- Hamartin tuberin complex</a></li></ul></li><li><div id=\"PULM/4335|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/66775\" class=\"graphic graphic_picture\">- Pulmonary LAM microscopy Low</a></li><li><a href=\"image.htm?imageKey=PULM/77252\" class=\"graphic graphic_picture\">- Pulmonary LAM microscopy High</a></li><li><a href=\"image.htm?imageKey=PULM/79407\" class=\"graphic graphic_picture\">- LAM in tuberous sclerosis</a></li><li><a href=\"image.htm?imageKey=PULM/64389\" class=\"graphic graphic_picture\">- Pulmonary LAM lung biopsy Low</a></li><li><a href=\"image.htm?imageKey=PULM/53690\" class=\"graphic graphic_picture\">- Pulmonary LAM lung biopsy High</a></li><li><a href=\"image.htm?imageKey=PULM/68405\" class=\"graphic graphic_picture\">- Cysts in LAM</a></li><li><a href=\"image.htm?imageKey=PULM/55243\" class=\"graphic graphic_picture\">- Pulmonary LAM HMB 45</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-clinical-presentation-and-diagnostic-evaluation\" class=\"medical medical_review\">Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sporadic-lymphangioleiomyomatosis-treatment-and-prognosis\" class=\"medical medical_review\">Sporadic lymphangioleiomyomatosis: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberous-sclerosis-complex-associated-lymphangioleiomyomatosis-in-adults\" class=\"medical medical_review\">Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberous-sclerosis-complex-genetics-clinical-features-and-diagnosis\" class=\"medical medical_review\">Tuberous sclerosis complex: Genetics, clinical features, and diagnosis</a></li></ul></div></div>","javascript":null}